Structure Therapeutics Inc. (NASDAQ:GPCR - Get Free Report)'s stock price gapped up prior to trading on Friday . The stock had previously closed at $29.97, but opened at $30.79. Structure Therapeutics shares last traded at $30.08, with a volume of 75,354 shares trading hands.
Analysts Set New Price Targets
GPCR has been the subject of several analyst reports. JMP Securities reiterated a "market outperform" rating and set a $91.00 price objective on shares of Structure Therapeutics in a research report on Wednesday. Cantor Fitzgerald reiterated an "overweight" rating and set a $65.00 price target on shares of Structure Therapeutics in a research report on Monday, September 23rd. Morgan Stanley initiated coverage on Structure Therapeutics in a research note on Monday, September 23rd. They issued an "overweight" rating and a $118.00 price target for the company. Finally, HC Wainwright restated a "buy" rating and set a $80.00 price objective on shares of Structure Therapeutics in a research note on Thursday. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has a consensus rating of "Buy" and an average target price of $86.50.
Check Out Our Latest Report on Structure Therapeutics
Structure Therapeutics Stock Performance
The stock has a market capitalization of $1.60 billion, a P/E ratio of -37.70 and a beta of -3.41. The business has a 50 day simple moving average of $35.32 and a 200-day simple moving average of $38.86.
Institutional Inflows and Outflows
Several large investors have recently bought and sold shares of GPCR. Sandia Investment Management LP acquired a new stake in Structure Therapeutics in the 2nd quarter valued at about $39,000. Assetmark Inc. lifted its stake in Structure Therapeutics by 120.0% during the third quarter. Assetmark Inc. now owns 1,318 shares of the company's stock valued at $58,000 after purchasing an additional 719 shares during the last quarter. Quarry LP acquired a new stake in Structure Therapeutics during the second quarter valued at approximately $79,000. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Structure Therapeutics by 60.1% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,784 shares of the company's stock worth $158,000 after buying an additional 1,420 shares in the last quarter. Finally, Dearborn Partners LLC acquired a new position in Structure Therapeutics in the third quarter worth approximately $202,000. Institutional investors own 91.78% of the company's stock.
Structure Therapeutics Company Profile
(
Get Free Report)
Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.
Featured Articles
Before you consider Structure Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Structure Therapeutics wasn't on the list.
While Structure Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
